XTRA:FREHealthcare
How Investors Are Reacting To Fresenius SE (XTRA:FRE) Doubling Biopharma Ambition By 2030
Earlier this month, Fresenius SE & Co. KGaA held its Analyst/Investor Day, outlining a plan to double its biopharma revenue and portfolio by 2030 while targeting a 20% EBIT margin through innovation, cost leadership, and global commercial expansion.
Management emphasized that a robust biopharma pipeline, strong underlying financial performance, and significant R&D and manufacturing investments are intended to support this long-term value creation roadmap.
We’ll now explore how Fresenius’s...